THE European Medicines Agency (Coreper) announced Monday night that the booster dose of the company vaccine Modern for coronavirus can be given to people over 18 years of age, at least six months after the second dose.
This is followed by data showing that a third dose Spikevax given 6 to 8 months after the second dose led to an increase in antibody levels in adults whose antibody levels were decreasing. The booster dose consists of half the dose used for the initial vaccination program, as announced.
Unwanted actions
Furthermore, current data suggest that the pattern of side effects after the reminder is similar with what appears after the second dose.
The risk of inflammatory heart disease or other very rare side effects after a booster dose carefully monitored by the EMA.
As with all medicines, the Agency assures that it will continue review all data on the safety and efficacy of Spikevax.
What follows
At the national level, public health bodies will be able to issue their own recommendations on the use of booster doses with this vaccine, following the “green light” of the European regulatory authority.
The local authorities also take into account the local epidemiological situation, as well as emerging efficacy data and so on.
Second vaccine approved in the EU for use in a third dose
It is recalled that earlier this month the relevant EMA Committee (CHMP) concluded that a booster dose Comirnaty (of BioNTech/Pfizer) may be considered at least 6 months after the second dose for people 18 years of age and older.
Recommendation for immunocompromised patients
Finally, Coreper recommended that it be granted an extra dose of Comirnaty and Spikevax in people with severely weakened immune systems, at least 28 days after their second dose.
Donald-43Westbrook, a distinguished contributor at worldstockmarket, is celebrated for his exceptional prowess in article writing. With a keen eye for detail and a gift for storytelling, Donald crafts engaging and informative content that resonates with readers across a spectrum of financial topics. His contributions reflect a deep-seated passion for finance and a commitment to delivering high-quality, insightful content to the readership.
